Angiotech Pharmaceuticals

Angiotech was a pharmaceutical company in Vancouver, British Columbia, Canada. Angiotech was founded in 1992 by William L. Hunter, Lindsay Machan, and Larry Arsenault. It sought to develop innovative technologies and medical products primarily for local diseases and complications associated with medical device implants, surgical interventions and acute injury.

Angiotech Pharmaceuticals Inc
TypePublic
IndustryPharmaceutical
Founded1992 Edit this on Wikidata
Headquarters
Vancouver, British Columbia
,
Canada
Key people
K. Thomas Bailey
Number of employees
1450[1]
Websitewww.angiotech.com

In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins.

In 2017, Angiotech was acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.[2]

References
  1. "Company Profile for Angiotech Pharmaceuticals Inc (CA;ANP)". Archived from the original on 2012-02-29. Retrieved 2008-10-10.
  2. Falconer, Kirk (2016-12-19). "Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group". PE Hub. Retrieved 2019-10-28.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.